| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PALB |
| Uniprot No | P02766 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-147aa |
| 氨基酸序列 | GPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE |
| 预测分子量 | 43.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于PALB重组蛋白研究的参考文献及其摘要概括：
---
1. **文献名称**：*"Structural and functional analysis of the PALB2 DNA-binding domain reveals its roles in BRCA2-related repair"*
**作者**：Xia, B., et al. (2020)
**摘要**：本研究通过重组表达人源PALB2蛋白的DNA结合域，解析其晶体结构，揭示了其与DNA及BRCA2复合物的相互作用机制，证实PALB2在DNA同源重组修复中的关键作用。
---
2. **文献名称**：*"Recombinant PALB2 phosphorylation modulates its interaction with BRCA1/2 in cancer susceptibility"*
**作者**：Park, J.Y., et al. (2018)
**摘要**：利用重组PALB2蛋白研究其磷酸化修饰对BRCA1/2结合的影响，发现特定磷酸化位点突变会破坏复合体稳定性，为乳腺癌遗传易感性提供了分子机制解释。
---
3. **文献名称**：*"Biochemical characterization of the PALB2-RAD51C interaction in homologous recombination repair"*
**作者**：Dray, E., et al. (2016)
**摘要**：通过重组表达纯化PALB2和RAD51C蛋白，结合体外Pull-down实验及功能分析，阐明二者直接互作对同源重组修复效率的调控作用，支持其在基因组稳定性中的重要性。
---
4. **文献名称**：*"Expression and purification of recombinant PALB2 for functional studies in Fanconi anemia pathway"*
**作者**：Zhang, Q., et al. (2019)
**摘要**：开发高效重组PALB2蛋白表达纯化系统，并验证其在范可尼贫血通路中的功能，证明其与FANCN的相互作用对修复DNA交联损伤至关重要。
---
**注**：以上文献为示例性内容，实际引用时需核实具体发表信息及原文内容。
**Background of PALB Recombinant Protein**
The PALB (Partner and Localizer of BRCA2) recombinant protein is derived from the PALB2 gene, a critical tumor suppressor involved in DNA repair and genome stability. PALB2 interacts directly with BRCA1 and BRCA2. forming a functional complex essential for homologous recombination repair (HRR) of double-strand DNA breaks. This pathway is vital for maintaining genomic integrity, and its disruption is linked to hereditary cancers, including breast, ovarian, and pancreatic cancers.
Recombinant PALB proteins are engineered in vitro using expression systems (e.g., bacterial, yeast, or mammalian cells) to produce purified, functional proteins for research and therapeutic applications. These proteins retain key domains for binding BRCA2. facilitating studies on DNA repair mechanisms, cancer biology, and synthetic lethality in BRCA-deficient cancers.
PALB2 mutations are associated with Fanconi anemia and increased cancer risk, making recombinant PALB2 a tool for functional assays to classify genetic variants (e.g., pathogenicity assessments). Structural studies using recombinant PALB2 have elucidated its role in BRCA2 recruitment to DNA damage sites and its interplay with other repair proteins.
Clinically, PALB recombinant proteins contribute to drug discovery, particularly in targeting HRR-deficient cancers via PARP inhibitors. Additionally, they aid in developing diagnostic biomarkers and gene therapies. Research continues to explore PALB2's broader roles in replication stress, cell cycle regulation, and immune response modulation, underscoring its therapeutic potential in precision oncology.
In summary, PALB recombinant proteins bridge molecular insights into DNA repair with translational applications, offering avenues for understanding carcinogenesis and advancing targeted cancer treatments.
×
